Post-GSK era: How to get to an academic marketing conference?

the post-GSK era of : How to get to the academic marketing conference? 2014/11/21
the Southern Metropolis Daily shared: "
guide reading because the Chinese Medical Association has just been revealed to be through the convening of academic conferencetwo two years to collect medical enterprise sponsorship fees of 820 million yuan, and the Shanghai blood conference "check-out" incident Some foreign companies believe that the future of the academic conference again "knife" expectations will further depress foreign investment in China's operations earlier this month in Shanghai Jiading held the blood annual meeting opened half suddenly terminated, more than 400 doctors from all over the country overnight check out, the reason for this amazing scene is because of the meeting compliance issues stepped on the red line, the opening ceremony when the Shanghai Health and Planning Commission Supervision Office to the scene ordered the end of the meeting, while the meeting officials and the leadership of the Standing Committee of the Institute was taken away from the conversation, and soon after the sponsors were interviewed According to IMS research, multinational pharmaceutical companies now account for only 24% of China's pharmaceutical market, a significantly lower share of the 27.7% four years ago because the Chinese Medical Association, a major member of the academic conference, has just been revealed to have collected 820 million yuan in sponsorship fees for medical enterprises through the convening of academic conferences for two years, and the "check-out" incident of the Shanghai blood conference Some foreign companies believe that the future of the academic conference again "knife" expectations will further depress foreign investment in China's operations well known for academic marketing in the form of academic conferences, is the norm for multinational pharmaceutical companies around the world and an important weapon for these pharmaceutical giants to maintain their ever-strong performance In the case of GSK, which was reported to have paid bribes through academic conferences, its performance fell sharply after it suspended its activities How to define whether to violate the law in the future, how to prevent "one size fits all", is the majority of pharmaceutical companies, especially in China multinational pharmaceutical companies are the most concerned about the topic how academic conferences affect performance
what does the conference mean for an innovative prescription drug business? The GSK case may provide an answer according to the police notification, GSK (China) large customer team, the marketing department of various business departments and other departments, is to invite medical institutions throughout the country to engage in medical work of non-state staff to participate in various domestic and foreign conferences sponsored and organized by them, through the payment of travel expenses, lecture fees, travel arrangements and other ways to bribe the medical personnel attending the meeting In order to achieve the support of the medical staff at the meeting, GSK (China) all kinds of drugs into the local medical institutions After the bribery case , GlaxoSmithKline finally decided to break its arms in order to maintain its base in China, and the academic conference was interrupted The reform resulted in a slight 0.2% drop in revenue from the company's pharmaceutical division in 2013 and a 4% drop in overall operating profit In the third quarter of last year, G SK's sales of prescription drugs and vaccines in the Chinese market were down 61% year-on-year because of the use of centralized tender procurement of drugs in public and health-care hospitals in China, but whether they can actually be sold to hospital patients will be prescribed by doctors In this way, the establishment of cooperative relations with doctors and hospital officials who have the power to use drugs often becomean an important purpose of sponsorship by major pharmaceutical companies GSK incident, multinational pharmaceutical companies in the Chinese people at risk, some companies to strengthen compliance adjustment, once also suspended academic activities, this time many pharmaceutical companies operating in China lamented that life is difficult data show that multinational drug companies grew more slowly in the first quarter of this year, even as some companies accelerated their growth in the second quarter take Novartis, for example, where growth slowed to 17 per cent in the first quarter and further to 13 per cent in the second quarter Novartis' portfolio covers cardiovascular, oncology and ophthalmic and generic sashimi in high demand in China GSK has yet to shake off the shadow of China's compliance investigation GSK's sales continued to decline in the second quarter, reaching 25%, more than in the first quarter in addition, data from domestic and foreign drug distribution giants also show that pharmaceutical academics will reduce the impact on foreign demand for drugs In the 2013 semi-annual report, Shanghai Pharma reported that in 2013, the company's joint venture and imported products accounted for 48.48 percent of sales, down 5.17 percent from last year local drug companies are still lamenting the strength of foreign investment
the decline of academic conferences, and the strengthening of the anti-corruption efforts that accompany them, is continuing to reduce the share of multinational pharmaceutical companies in China This is the Speech and interactive session of Wang Lei, Vice President of AstraZeneca Investment (China) Co., Ltd., at the Shanghai Roundtable on Health Policy hosted by China Europe International Business School in September 2014 according to the According to IMS research, multinational pharmaceutical companies account for only 24% of China's pharmaceutical market, through the observation in recent quarters, the market growth rate of foreign enterprises is slower than the market average, so the proportion of foreign enterprises is expected to continue to decline 24% of the data are significantly lower than four years ago, according to the China Association of Foreign Investment Enterprises Drug Development and Development Industry Committee data, in 2010 the share of multinational pharmaceutical companies in China's pharmaceutical market was 27.7%, this part of the market by about 25 large multinational pharmaceutical companies, while the remaining 72.3 percent of the market, by more than 8,000 local pharmaceutical companies divided The data source of the China Association of Foreign Investment Enterprises's Pharmaceutical Development and Development Industry Committee is mainly based on IMS, but domestic pharmaceutical companies generally do not agree with this data In their view, foreign pharmaceutical companies already occupy half of China's pharmaceutical market The Chinese Drug Market Report, released in 2013 by the Chinese Academy of Social Sciences, points out that foreign-funded drugs dominate the market share in the high-speed expansion of the drug market In the second and third-level hospital market share of the top 10 enterprises are foreign or joint venture pharmaceutical enterprises mainly it is learned that in 2011, the Academy of Social Sciences on pharmaceutical companies in the hospital market share ranking shows that in the three-level hospitals, the top 10 enterprises, 8 are foreign-funded enterprises, only Shandong Qilu and Jiangsu Hengrui among the top 10, the top five Pfizer, AstraZeneca, Sanofi, Bayer, Roche are foreign-funded enterprises, GlaxoSmithKline was ranked ninth In the second-tier hospitals, Chinese companies ranked slightly better, but foreign pharmaceutical companies still accounted for an absolute share, with a total of six enterprises in the top 10 the National Cancer Registry this year's data also refers to the domestic sample hospital anti-tumor mono-anti-drug market of about 90% of the market, occupied by foreign drugs " in China's high-end hospital market drug field, innovative drugs-based joint venture foreign drugs have accounted for 48% of the share, and continue to eat into the share of domestic drugs; And domestic first-class new drugs sales proportion of less than 5% At the same time, in recent years, major international multinational pharmaceutical giants have set up nearly 20 drug research and development centers in China, further robbing China's drug research and development resources, to the already weak competition environment for drug research and development in China has brought many adverse factors Xiao Wei, a representative of the National People's Congress and chairman of Kangyuan Pharmaceuticals, has specifically suggested that governments at all levels should further increase their support for domestic drug independent innovation enterprises foreign investment still dominates the hospital market
the Chinese Drug Market Report released by the Chinese Academy of Social Sciences in 2013 has pointed out that foreign drugs dominate the market share in the high-speed expansion of the drug market In the second and third-level hospital market share of the top 10 enterprises are foreign or joint venture pharmaceutical enterprises mainly , it is learned that in 2011, the Academy of Social Sciences on pharmaceutical companies in the hospital market share ranking shows that in the three-level hospitals, the top 10 enterprises, 8 are foreign-funded enterprises, only Shandong Qilu and Jiangsu Hengrui among the top 10, the top five Pfizer, AstraZeneca, Sanofi, Bayer, Roche enterprises are foreign-funded enterprises, GlaxoSmithKline was ranked ninth In the second-tier hospitals, Chinese companies ranked slightly better, but foreign pharmaceutical companies still accounted for an absolute share, with a total of six enterprises in the top 10 2011, the Academy of Social Sciences' market share ranking of pharmaceutical companies in hospitals showed that 8 of the top 10 companies in tertiary hospitals were foreign-funded enterprises second-tier hospitals, Chinese companies ranked slightly better, with four companies making it into the top 10. Collection (
0 ) recommended (
0 )